Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 238

1.

Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains.

Walker DG, Lue LF, Adler CH, Shill HA, Caviness JN, Sabbagh MN, Akiyama H, Serrano GE, Sue LI, Beach TG; Arizona Parkinson Disease Consortium..

Exp Neurol. 2013 Feb;240:190-204. doi: 10.1016/j.expneurol.2012.11.020.

2.

Clinical and biochemical correlates of insoluble alpha-synuclein in dementia with Lewy bodies.

Klucken J, Ingelsson M, Shin Y, Irizarry MC, Hedley-Whyte ET, Frosch M, Growdon J, McLean P, Hyman BT.

Acta Neuropathol. 2006 Feb;111(2):101-8.

PMID:
16482476
3.

A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders.

Jellinger KA.

Biochim Biophys Acta. 2009 Jul;1792(7):730-40. doi: 10.1016/j.bbadis.2008.07.006. Review.

4.

Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases.

Pletnikova O, West N, Lee MK, Rudow GL, Skolasky RL, Dawson TM, Marsh L, Troncoso JC.

Neurobiol Aging. 2005 Aug-Sep;26(8):1183-92.

PMID:
15917102
5.

Lewy body-related alpha-synucleinopathy in the aged human brain.

Jellinger KA.

J Neural Transm (Vienna). 2004 Oct;111(10-11):1219-35.

PMID:
15480835
6.

Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease.

Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, Barbour R, Huang J, Kling K, Lee M, Diep L, Keim PS, Shen X, Chataway T, Schlossmacher MG, Seubert P, Schenk D, Sinha S, Gai WP, Chilcote TJ.

J Biol Chem. 2006 Oct 6;281(40):29739-52.

7.

Progression and staging of Lewy pathology in brains from patients with dementia with Lewy bodies.

Marui W, Iseki E, Nakai T, Miura S, Kato M, Uéda K, Kosaka K.

J Neurol Sci. 2002 Mar 30;195(2):153-9.

PMID:
11897247
8.

Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases.

Mamais A, Raja M, Manzoni C, Dihanich S, Lees A, Moore D, Lewis PA, Bandopadhyay R.

Neurobiol Dis. 2013 Oct;58:183-90. doi: 10.1016/j.nbd.2013.05.017.

9.

Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain.

Roberts RF, Wade-Martins R, Alegre-Abarrategui J.

Brain. 2015 Jun;138(Pt 6):1642-57. doi: 10.1093/brain/awv040.

10.

Changes in the solubility and phosphorylation of α-synuclein over the course of Parkinson's disease.

Zhou J, Broe M, Huang Y, Anderson JP, Gai WP, Milward EA, Porritt M, Howells D, Hughes AJ, Wang X, Halliday GM.

Acta Neuropathol. 2011 Jun;121(6):695-704. doi: 10.1007/s00401-011-0815-1.

PMID:
21400129
11.

Accumulation of insoluble alpha-synuclein in dementia with Lewy bodies.

Campbell BC, Li QX, Culvenor JG, Jäkälä P, Cappai R, Beyreuther K, Masters CL, McLean CA.

Neurobiol Dis. 2000 Jun;7(3):192-200.

PMID:
10860784
12.

α-synuclein phosphorylation and truncation are normal events in the adult human brain.

Muntané G, Ferrer I, Martinez-Vicente M.

Neuroscience. 2012 Jan 3;200:106-19. doi: 10.1016/j.neuroscience.2011.10.042.

PMID:
22079575
13.

Early alpha-synuclein lipoxidation in neocortex in Lewy body diseases.

Dalfó E, Ferrer I.

Neurobiol Aging. 2008 Mar;29(3):408-17.

PMID:
17166629
14.

The brainstem pathologies of Parkinson's disease and dementia with Lewy bodies.

Seidel K, Mahlke J, Siswanto S, Krüger R, Heinsen H, Auburger G, Bouzrou M, Grinberg LT, Wicht H, Korf HW, den Dunnen W, Rüb U.

Brain Pathol. 2015 Mar;25(2):121-35. doi: 10.1111/bpa.12168.

15.

Formation and development of Lewy pathology: a critical update.

Jellinger KA.

J Neurol. 2009 Aug;256 Suppl 3:270-9. doi: 10.1007/s00415-009-5243-y. Review.

PMID:
19711116
16.

Lewy-like aggregation of α-synuclein reduces protein phosphatase 2A activity in vitro and in vivo.

Wu J, Lou H, Alerte TN, Stachowski EK, Chen J, Singleton AB, Hamilton RL, Perez RG.

Neuroscience. 2012 Apr 5;207:288-97. doi: 10.1016/j.neuroscience.2012.01.028.

17.

Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies.

Arima K, Hirai S, Sunohara N, Aoto K, Izumiyama Y, Uéda K, Ikeda K, Kawai M.

Brain Res. 1999 Oct 2;843(1-2):53-61.

PMID:
10528110
18.

Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.

Tong J, Wong H, Guttman M, Ang LC, Forno LS, Shimadzu M, Rajput AH, Muenter MD, Kish SJ, Hornykiewicz O, Furukawa Y.

Brain. 2010 Jan;133(Pt 1):172-88. doi: 10.1093/brain/awp282.

PMID:
19903734
19.

Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies.

Muntané G, Dalfó E, Martinez A, Ferrer I.

Neuroscience. 2008 Apr 9;152(4):913-23. doi: 10.1016/j.neuroscience.2008.01.030.

PMID:
18343584
20.

Relationship of phosphorylated alpha-synuclein and tau accumulation to Abeta deposition in the cerebral cortex of dementia with Lewy bodies.

Obi K, Akiyama H, Kondo H, Shimomura Y, Hasegawa M, Iwatsubo T, Mizuno Y, Mochizuki H.

Exp Neurol. 2008 Apr;210(2):409-20. doi: 10.1016/j.expneurol.2007.11.019.

PMID:
18164295
Items per page

Supplemental Content

Support Center